Literature DB >> 15664682

[Treatment of ejaculation disorders by midodrine (Gutron) per os. Retrospective study of about 16 subjects].

A Blanchard-Dauphin1, J M Rigot, A Thevenon.   

Abstract

PURPOSE: We evaluate the efficiency and side effects of midodrine in the treatment of sperm transport disturbances.
MATERIALS AND METHODS: This retrospective study concerned patients addressed in Andrologia Department between 1995 and 2002 for treatment of sperm transport disturbances by administration of Midodrine per os (from 2.5 to 20 mg). Anterograde and retrogrades ejaculates (in urine sample) were examined.
RESULTS: Sixteen patients (middle age of 36 years) were included: 12 neurologic lesions (central or peripheral, with 3 diabetes), four post-surgical (urologic and digestive) ejaculatory incompetence. One patient obtained anterior and retrograde ejaculation, two patients obtained anterior ejaculation and six retrograde ejaculations by midodrine per os. This treatment was inefficient in eight subjects. Side effects were exceptional. DISCUSSION: We obtained anterior or retrograde ejaculation in half of our population. The success was more important in patients with central neurologic injuries, diabetes or post-surgical troubles. In peripheral neurologic injuries, midodrine per os (maximal dose of 20 mg) was ineffective.
CONCLUSION: Our study demonstrates the efficiency and good tolerance of midodrine per os for treatment of sperm transport disturbances.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15664682     DOI: 10.1016/j.annrmp.2004.09.004

Source DB:  PubMed          Journal:  Ann Readapt Med Phys        ISSN: 0168-6054


  2 in total

Review 1.  Male sexual dysfunction and infertility associated with neurological disorders.

Authors:  Mikkel Fode; Sheila Krogh-Jespersen; Nancy L Brackett; Dana A Ohl; Charles M Lynne; Jens Sønksen
Journal:  Asian J Androl       Date:  2011-12-05       Impact factor: 3.285

Review 2.  Preclinical evidence supporting the clinical development of central pattern generator-modulating therapies for chronic spinal cord-injured patients.

Authors:  Pierre A Guertin
Journal:  Front Hum Neurosci       Date:  2014-05-30       Impact factor: 3.169

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.